Tag Archives: launching

The ‘Fallasiz Dreams launch event’ was held in Karachi | Instant News

KARACHI – Fallasiz Dreams, a mega residential project by the Fallasiz Group, was launched at a grand ceremony held in Karachi. Organized by ilaan.com, this ceremony is a family event where various activities are planned for the participants. During the event, exclusive discounts are offered to investors and general buyers. Discounts are limited to events only. The event consists of a project briefing, musical evening and dinner. A large number of prominent figures from the real estate fraternity attended the event with their families including. The core team members of ilaan.com were also present at the occasion including CEO Mian Omer, Operations Manager Mian Sheraz, Operations Manager Mahvash Khan, Public Relations Manager Humna Syed, Head of Operations Country Head Major Atique, advisor Sardar Rashid, Country Project Sales M Asad, and Regional Sales Manager Hafiz Ubaid. AKRA members also attended including President Rehman and Kamran Nawaz. Fal artiz The Dreams is a new residential project by Fallasiz where a plot for a luxury villa is offered in easy monthly installment packages. Pakistan’s fastest growing property website, ilaan.com, is marketing the project and all project details are available on the portal.


image source

Customs and Excise launched a trade facilitation program | Instant News

ISLAMABAD: Pakistani Customs has launched the first trade facilitation program of its kind under the name “Official Economic Operator” through the operation of the “AEO Pilot Project” in Karachi. This program has been recognized as being in line with international best practice and conforming to WCO safety standards.

Under the program, the government will certify trustworthy business entities that can demonstrate that they are trustworthy, secure and have a history of clean compliance with national laws and, in exchange, a non-interference policy will be adopted by all government departments against trusted entities. of these, so they can concentrate on growing their business. The AEO program is a major step towards merchant facilitation and ease of doing business as the “red tape” of government departments will be replaced by “red carpets” for trustworthy enterprises, and will provide an enabling environment for the business community to achieve their maximum results. potency.

The AEO Pilot Project is the first step that has been launched at the Customs Collectorate of Port Qasim, Karachi, through the inclusion of M / s Artistic Denim Mills, Karachi, which is a well-known textile sector producer and exporter. Initially, the AEO Pilot Project has been launched at the export stage and gradually other supply chain areas will be incorporated into the pilot project and finally the AEO Program will be launched to facilitate the business community. Merchants and various chamber associations have appreciated the government’s AEO initiative and say that this is the first of its kind aimed at the recognition of trusted business partners at the federal government level and requires the benefits of all government departments.

Business actors hope that this unique initiative has great potential to encourage export-oriented business actors who are the backbone of the national economy.


image source

PM Imran will launch the CPEC City project | Instant News

NOWSHERA: Federal Defense Minister Pervez Khattak said PM Imran Khan will launch a job in Rashakai City ‘China-Pakistan Economic Corridor (CPEC)’ on 18 November. “The city will be built under CPEC and will consist of educational and commercial zones, public buildings, apartments, golf courses, amusement parks and sports facilities,” the federal minister said while speaking at a public meeting in Abakhel, Nowshera Kalaan.


image source

Diurnal: The Market Authorization Application for Alkindi® is submitted to Swissmedic | Instant News

Posted on Wednesday, 21 / Oct / 2020 Posted by michelle

Swiss partner EffRx Pharmaceuticals expects a market launch in 2022

Diurnal Group plc (AIM: DNL), a specialized pharmaceutical company targeting the needs of patients in chronic endocrine (hormonal) diseases, announced that the Company’s marketing and distribution partner in Switzerland, EffRx Pharmaceuticals (EffRx), has submitted a Market Authorization Application (MAA) to Swissmedic for Alkindi registration® (hydrocortisone granules in capsules for opening) in Switzerland.

MAA submission to Swissmedic for Alkindi® based on European regulatory files and published clinical trial data, with EffRx expecting a potential market launch in Switzerland by 2022.There are about 200 patients in Switzerland with pediatric AI, providing an estimate of the total market opportunity for Alkindi® about $ 1 million per year. As previously announced under the terms of the agreement, EffRx will receive the exclusive rights to market and sell Alkindi® in Switzerland once registered.

Alkindi® approved and marketed in Europe and is the first hydrocortisone preparation (synthetic version of cortisol) specifically designed for use in children with AI, including CAH-related conditions.

Diurnal will provide EffRx with products for sale from an established European supply chain and are part of the Company’s ongoing strategy for commercialization of its main products by optimizing market access outside of Europe’s main markets through marketing and distribution agreements with niche-focused and orphaned companies. condition.

Martin Whitaker, CEO of Diurnal, comments:

‘We are very pleased to see the MAA submission for Alkindi® in Switzerland by EffRx. Today’s announcement is a further validation of the quality of our products and extends Alkindi’s future availability® outside our core markets in line with our global strategy. We look forward to working with EffRx to create Alkindi® available to patients suffering from pediatric AI in Switzerland. ‘

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For more information, please visit www.diurnal.co.ukor contact:

Diurnal group plc +44 (0) 20 3727 1000
Martin Whitaker, Executive Director
Richard Bungay, Director of Finance

Panmure Gordon (UK) Limited (Nomination Advisor and Joint Brokerage) +44 (0) 20 7886 2500
Corporate Finance: Freddy Crossley, Emma Earl
Broking Company: Rupert Dearden

Consultation FTI +44 (0) 20 3727 1000
Simon Conway
Victoria Foster Mitchell

Notes to Editors

About Alkindi® (hydrocortisone granules in capsules for opening)
Alkindi® is the first hydrocortisone preparation specifically designed for use in children with pediatric adrenal insufficiency (AI). Alkindi® is a patented, oral, immediately released hydrocortisone formulation for children in a capsule for the opening that allows age-appropriate dosing in children. This therapeutic approach has the potential to help young patients aged less than eighteen who suffer from cortisol deficiency diseases including AI in children and congenital adrenal hyperplasia (CAH). AI requires lifelong treatment and Diurnal’s new approach to product development has the potential to significantly improve the lives of young patients. The European Commission has granted a pediatric use marketing authorization (PUMA) for Alkindi® as replacement therapy for AI in infants, children and adolescents (from birth to

Alkindi® also approved in Israel and Australia.

Alkindi® known as Alkindi® Sprinkle in the US and approved by the US Food and Drug Administration (FDA) on September 29, 2020.

About Pediatric Adrenal Insufficiency
AI in children, including the genetic condition CAH is a condition characterized by a deficiency of cortisol, an essential hormone in the regulation of metabolism and response to stress. The main symptom of AI is chronic fatigue and patients are at risk for adrenal crisis and death if they are not given adequate cortisol replacement. AI is primary or secondary, with primary AI due to disease intrinsic to the adrenal glands and AI secondary to pituitary disease where there is failure of adrenal stimulation by the pituitary of the signaling hormone ACTH (adrenocorticotropic hormone).

About Diurnal Group plc
Founded in 2004, Diurnal is a European specialty pharmaceutical company headquartered in the UK that develops high quality products for the global market for the lifelong treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, and hypogonadism. Her expertise and innovative research activities focus on circadian-based endocrinology to produce new product candidates in the arena of rare and chronic endocrine diseases.

For more information about Diurnal, please visit www.diurnal.co.uk

About EffRx Pharmaceuticals
EffRx Pharmaceuticals is a commercial-stage pharmaceutical company focused on the late-stage development and commercialization of prescription drugs for special indications and orphanages. The business model is centered on providing superior clinical and commercial value propositions for clinicians, payers and patients. EffRx is pro-actively exploring licensing opportunities for Europe in the specialty therapy field, with particular interest for rare diseases, for which EffRx has received the FDA’s orphaned drug (ODD) designation for pipeline assets.

For more information on EffRx Pharmaceuticals, please visit www.effrx.com

Preparation date: October 2020 Code: CORP-GB-0087

See the pdf document: The Market Authorization application for Alkindi® was submitted to Swissmedic


Diurnal group plc publish this content on 21 October 2020 and take full responsibility for the information contained therein. Distributed by the Public, unedited and unaltered, at October 21 2020 06:09:05 UTC


image source